New Delhi, March 23 -- The generic semaglutide has entered the Indian market at a huge discount compared to innovator products already available, according to an expert from AIIMS, Dr Nikhil Tandon, professor and HOD of the Department of Endocrinology and Metabolism.

Dr Nikhil Tandon told ANI, "One should not consume it (generic semaglutide) recklessly as these are serious medicines for a serious problem. People should be careful, as there can be side effects."

With the patent expirations for GLP-1 drugs, used for treating type 2 diabetes and obesity, major Pharma companies in India are lining up cheaper generic alternatives.

These alternatives are likely to be priced at a significantly lower price as compared to the current costs. Acc...